G2X TAKE: Amy Abernethy, who for the past two years has helped oversee the Agency’s day-to-day functioning and directed special and high-priority initiatives that cut across offices overseeing FDA’s regulation of drugs, medical devices, tobacco and food, and who also served as the Acting Chief Information Officer (CIO), responsible for oversight of the trans-agency technical and data-focused vision plus its implementation, has announced a departure from the Food and Drug Administration.
In announcing the move, Dr. Abernethy noted: “It has been an honor to serve as the FDA’s Principal Deputy Commissioner & Acting CIO. Over the last 2+ years, we developed the data & tech modernization plans, made progress in challenging areas like CBD, stood up the Evidence Accelerator, all while ensuring that we are advancing precision medicine in service of the patient…A huge thank you to the leadership of Janet Woodcock; it has been a pleasure and honor to work together with you at FDA and especially during this transition. And a mighty thank you to my FDA colleagues…” See the full post here.
Dr. Abernethy was recently recognized among the FedHealthIT100, an award that honors those individuals recognized for driving change and advancement in the Federal Health Information Technology and Consulting Market.
There was no additional information as to her next steps but given her depth of insight and experience, many will be reaching out to offer congratulations and perhaps to see what may be next. There is no information at this time as to who will be stepping in to fill these roles.
Prior roles include:
- Principal Deputy Commissioner & Acting CIO – US Food & Drug Administration
- Chief Medical Officer/Chief Scientific Officer & SVP Oncology – Flatiron Health
- Director – athenahealth, Inc